Sign in
CompletedPhase 3

ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO)

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
240 people enrolled
Started
3 Jul 2019
Ended
18 Jan 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ILOPROST
  • NaCl
Record updated
3 July 2024

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients over 18 years of age
  • Signed informed consent or inclusion under the emergency provisions of the law (Article L1122 -1-3 of the PHC / modified by Order n°2016-800 of June 16 2016 - art. 2)
  • Patients with septic shock defined by the third international definition:; suspected or proven infection,; and organ dysfunction defined by an acute change in total SOFA score >or=2; and persistent hypotension requiring vasopressor treatment to maintain mean arterial pressure > 65 mmHg despite standard of care hemodynamic optimization; and serum lactate level > 2 mmol/L despite standard of care hemodynamic optimization; and persistence of peripheral hypoperfusion (skin mottling and/or finger skin recoloration time > 3sec, and/or knee skin recoloration time > 4sec) despite standard of care hemodynamic optimization; Within 6 to 24 hours after norepinephrine onset

Who cannot take part

  • Hypersensitivity to Ilomedin or to any of the excipients
  • unstable angina
  • severe cardiac rhythm disorders since Norepinephrine onset
  • myocardial infarction in the last 6 months
  • Conditions where the hemorrhagic risk may be increased due to the effects of Ilomedin on platelets (i.e., evolving hemorrhage, trauma, intracranial hemorrhage, active gastric ulcer)
  • Platelet count < 10000 /mm3
  • Refusal to participate in the study
  • Pregnancy, breastfeeding
  • severe hypoxemia (PaO2/FiO2 <100)
  • lack of Social Insurance
  • persons deprived of liberty
  • persons of a protective measure

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Septic shock remains a major cause of death in critically ill patients. Alterations in microcirculation have long been proposed as a key pathophysiological factor of organ dysfunction and death in septic shock patients. Persistence of mottling, prolonged skin recoloration time and cyanosis of the extremities are the easily and frequently observed manifestations of these microcirculatory disorders. Ilomedin is a prostaglandin analog with a potent vasodilatory effect together with anti-thrombotic properties (inhibition of platelet aggregation) preferentially at the microcirculatory level. An increase in cardiac output with increased arterial oxygen delivery has been observed in clinical and preclinical studies with no episodes of hypotension. Improvement in mesenteric perfusion has moreover been observed in experimental sepsis using Ilomedin. Our group has furthermore reported that administration of Ilomedin in patients with refractory septic shock (peripheral hypoperfusion) resulted in a rapid and sustained improvement in peripheral perfusion. Altogether, Ilomedin may prevent or improve recovery of organ dysfunction in septic shock patients through recruitment of the microcirculation and, thereby, ultimately improve outcome.

The 2 groups in the trial

  • intravenous ILOPROSTTreatment being tested

    a first dose of ILOPROST of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h

    Treatment: ILOPROST

  • Intravenous PlaceboPlacebo, for comparison

    Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h

    Treatment: NaCl

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
" ILOPROST for Treatment of Septic Shock With Persistent Microperfusion Defects ", a Double-blind, Randomized Controlled Trial:The I-MICRO Trial
Publications
Record updated
3 July 2024